Respira Labs is excited to announce that we have been issued US Patent No. 10,709 by the United States Patent and Trademark Office (USPTO) on July 14, 2020. The patent was approved to develop technology in the form of acoustic sensors to detect abnormal volumes of air inside of the lungs air trapping (AT). This patent was granted in less than one year, which is record time compared to typical patent approval waiting times which average about 22 months.
Respira Labs utilizes a multidisciplinary approach, where technology is developed in parallel to clinical testing. Through peer review and support from prestigious organizations such as the National Science Foundation (NSF) and National Institutes of Health (NIH), Respira Labs has been recognized as “one of the upcoming leaders in respiratory health” (Dr. Maria Artunduaga) .
Respira Labs is expected to enter the market as soon as 2023 under FDA 510(k) clearance.
Intellectual Property Protection
With the issuance of the patent, Respira Labs will be developing new and innovative technology in a form that isn’t currently available, a wearable device. This technology consists of acoustic sensors to detect abnormal volumes of air inside of the lungs air trapping.
Given Respira Lab’s innovative and unique approach to Chronic Obstructive Pulmonary Disease (COPD) care, this issuance is incredibly important in protecting the years of research and development (R&D) by the Respira Labs team.
Air trapping within the lungs is often associated with Chronic Obstructive Pulmonary Disease exacerbation (COPDe). COPDe’s is one of the main reasons for COPD hospitalizations and in general, lower quality of life for patients. Therefore, the technology being developed through this patent is highly relevant for the 12 million Americans who have been diagnosed with COPD and another 17 million that may have COPD. In addition, an estimated 328 million people have COPD worldwide, which translates to a worldwide need. (World Health Organization) .
The NHBLI STTR grant brings Respira Labs one step closer to the fight against chronic lung diseases, like COPD and Covid. It has been found that 1/3 of recovered Coronavirus patients develop air trapping in the long term. This condition exacerbates the sequela in pulmonary patients through the deterioration of the lungs ability to work well and the negative effect on one's quality of life. Due to this, COVID is expected to increase the prevalence of chronic respiratory diseases by 25%.
About Respira Labs
Respira Labs is developing the first wearable device to measure air trapping, a marker of COPD progression and COPD attacks. Respira Labs aims to save lives and revolutionize COPD management, significantly improving patient’s quality of life. For this reason, we are developing the first wearable device equipped with early diagnosis of COPD exacerbation attacks in real-time.
The core technology combines lung physiology, signal processing, connected sensors, and Machine Learning.
If you are diagnosed with COPD and are interested in taking part in clinical trials for
Respira Labs, please contact UCSF Professor Mehrdad Arjomandi at
Mehrdad.Arjomandi@ucsf.edu and visit his lab website at https://arjomandilab.ucsf.edu/.
To learn more about our clinical trials visit our clinical trial study record here: https://clinicaltrials.gov/ct2/show/NCT04450368.
If you are interested in working for Respira Labs, please contact Dr. Maria Artunduaga at email@example.com.
Respira Labs is very grateful for all the support, make sure to sign up for more updates